¿NECESITA INSCRIBIRSE? Busque entre nuestros planes
Clinical & Payment Policies | Ambetter de MHS
Políticas clínicas y de pago
Clinical Policies
Clinical policies are one set of guidelines used to assist in administering health plan benefits, either by prior authorization or payment rules. They include but are not limited to policies relating to evolving medical technologies and procedures, as well as pharmacy policies. Clinical policies help identify whether services are medically necessary based on information found in generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by the policy; and other available clinical information.
All policies found in the MHS Clinical Policy Manual apply to MHS members. Policies in the MHS Clinical Policy Manual may have either a MHS or a “Centene” heading. MHS utilizes MCG criteria for those medical technologies, procedures or pharmaceutical treatments for which a MHS clinical policy does not exist. MCG is a nationally recognized evidence-based decision support tool. In addition, MHS may from time to time delegate utilization management of specific services; in such circumstances, the delegated vendor’s guidelines may also be used to support medical necessity and other coverage determinations. Other non-clinical policies (e.g., payment policies) or contract terms may further determine whether a technology, procedure or treatment that is not addressed in the Clinical Policy Manuals or MCG criteria is payable by MHS.
If you have any questions regarding these policies, please contact Member Services and ask to be directed to the Medical Management department.
Ambetter Clinical Policies
- 25-hydroxyvitamin D Testing in Children and Adolescents (CP.MP.157) (PDF)
- Acupuncture (CP.MP.92) (PDF)
- ADHD Assessment and Treatment (CP.MP.124) (PDF)
- Air Ambulance (CP.MP.175) (PDF)
- Allergy Testing and Therapy (CP.MP.100) (PDF)
- Allogenic Hematopoietic Cell Transplants for Sickle Cell Anemia and Beta-Thalassemia (CP.MP.108) (PDF)
- Ambulatory Surgery Center Optimization (CP.MP.158) (PDF)
- Anesthesiology Services for Gastrointestinal Endoscopy (CP.MP.161) (PDF)
- Applied Behavioral Analysis (CP.BH.104) (PDF)
- Articular Cartilage Defect Repairs (CP.MP.26) (PDF)
- Assisted Reproductive Technology (CP.MP.55) (PDF)
- Bariatric Surgery (CP.MP.37) (PDF)
- BH Treatment Documentation Requirements (CP.BH.500) (PDF)
- Biofeedback for BH Disorders (CP.BH.300) (PDF)
- Bone-Anchored Hearing Aid (CP.MP.93) (PDF)
- Bronchial Thermoplasty (CP.MP.110) (PDF)
- Burn Surgery (CP.MP.186) (PDF)
- Cardiac Biomarker Testing (CP.MP.156) (PDF)
- Cardiac Rehabilitation (CP.MP.176) (PDF)
- Carrier Screening in Pregnancy (CP.MP.83) (PDF)
- Caudal or Interlaminar Epidural Steroid Injections (CP.MP.164) (PDF)
- Clinical Trials (CP.MP.94) (PDF)
- Cochlear Implant Replacements (CP.MP.14) (PDF)
- Cosmetic and Reconstructive Surgery (CP.MP.31) (PDF)
- Deep Transcranial Magnetic Stimulation for Treatment of Obsessive Compulsive Disorder (CP.BH.201) (PDF)
- Dental Anesthesia (CP.MP.61) (PDF)
- Diagnostic Testing for Zika Virus (CP.MP.111) (PDF)
- Diaphragmatic/Phrenic Nerve Stimulation (CP.MP.203) (PDF)
- Digital Electroencephalography Spike Analysis (CP.MP.105) (PDF)
- Disc Decompression Procedures (CP.MP.114) (PDF)
- Discography (CP.MP.115) (PDF)
- Donor Lymphocyte Infusion (CP.MP.101) (PDF)
- Drugs of Abuse: Definitive Testing (CP.MP.50) (PDF)
- Durable Medical Equipment (DME) (CP.MP.107) (PDF)
- Electric Tumor Treating Fields (CP.MP.145) (PDF)
- Electroencephalography in the Evaluation of Headache (CP.MP.155) (PDF)
- Endometrial Ablation (CP.MP.106) (PDF)
- Evoked Potential Testing (CP.MP.134)(PDF)
- Experimental Technologies (CP.MP.36) (PDF)
- Facet Joint Interventions (CP.MP.171) (PDF)
- Fecal Calprotectin Assay (CP.MP.135) (PDF)
- Fecal Incontinenece Treatment (CP.MP.137) (PDF)
- Ferriscan R2-MRI (CP.MP.53) (PDF)
- Fertility Preservation (CP.MP.130) (PDF)
- Fetal Surgery in Utero for Prenatally Diagnosed Malformations (CP.MP.129) (PDF)
- Functional MRI (CP.MP.43) (PDF)
- Gastric Electrical Stimulation (CP.MP.40) (PDF)
- Gender-Affirming Procedures (CP.MP.95) (PDF)
- GI Pathogen Panel Testing (CP.MP.209) (PDF)
- H. Pylori Serology Testing (CP.MP.153) (PDF)
- Heart Lung Transplant (CP.MP.132) (PDF)
- Holter Monitor (CP.MP.113) (PDF)
- Home Birth (CP.MP.136) (PDF)
- Home Photothereapy for Neonatal Hyperbilirubienemia (CP.MP.150) (PDF)
- Home Ventilator (CP.MP.184) (PDF)
- Homocysteine Testing (CP.MP.121) (PDF)
- Hospice Services (CP.MP.54) (PDF)
- Hyperbaric Oxygen Therapy (CP.MP.27) (PDF)
- Hyperemesis Gravidarum Treatment (CP.MP.34) (PDF)
- Hyperhidrosis Treatments (CP.MP.62) (PDF)
- Implantable Intrathecal Pain Pump (CP.MP.173) (PDF)
- Implantable Loop Recorder (CP.MP.243) (PDF)
- Implantable Wireless Pulmonary Artery Pressure Monitor (CP.MP.160) (PDF)
- Inhaled Nitric Oxide (CP.MP.87) (PDF)
- Intensity-Modulated Radiotherapy (CP.MP.69) (PDF)
- Intestinal and Multivisceral Transplant (CP.MP.58) (PDF)
- Intradiscal Steroid Injections for Pain Management (CP.MP.167) (PDF)
- Laser Therapy for Skin Conditions (CP.MP.123) (PDF)
- Long Term Care Placement Criteria (CP.MP.71) (PDF)
- Low-Frequency Ultrasound Therapy for Wound Management (CP.MP.139) (PDF)
- Lung Transplantation (CP.MP.57) (PDF)
- Lysis of Epidural Lesions (CP.MP.116) (PDF)
- Mechanical Stretching Devices for Joint Stiffness and Contracture (CP.MP.144) (PDF)
- Measurement of Serum 1,25-dihydroxyvitamin D (CP.MP.152) (PDF)
- Monitored Anesthesia Care (CP.MP.161) (PDF)
- Multiple Sleep Latency Testing (CP.MP.24) (PDF)
- Neonatal Abstinence Syndrome Guidelines (CP.MP.86) (PDF)
- Neonatal Sepsis Management (CP.MP.85) (PDF)
- Nerve Blocks for Pain Management (CP.MP.170) (PDF)
- Neuromuscular Electrical Stimulation (NMES) (CP.MP.48) (PDF)
- NICU Apnea Bradycardia Guidelines (CP.MP.82) (PDF)
- NICU Discharge Guidelines (CP.MP.81) (PDF)
- Non-Myeloablative Allogeneic Stem Cell Transplants (CP.MP.141) (PDF)
- Obstetrical Home Health Care Programs (CP.MP.91) (PDF)
- Optic Nerve Decompression Surgery (CP.MP.128) (PDF)
- Orthognathic Surgery (CP.MP.202) (PDF)
- Osteogenic Stimulation (CP.MP.194) (PDF)
- Outpatient Testing for Drugs of Abuse (CP.MP.50) (PDF)
- Oxygen Use and Concentrators (CP.MP.190) (PDF)
- Pancreas Transplant (CP.MP.102) (PDF)
- Panniculectomy (CP.MP.109) (PDF)
- Pediatric Heart Transplant (CP.MP.138) (PDF)
- Pediatric Kidney Transplant (CP.MP.246) (PDF)
- Pediatric Liver Transplant (CP.MP.120) (PDF)
- Percutaneous Left Atrial Appendage Closure Device for Stroke Prevention (CP.MP.147) (PDF)
- Physical, Occupational, and Speach Therapy Services (CP.MP.49) (PDF)
- Post-Acute Care (CP.MP.213) (PDF)
- Posterior Tibial Nerve Stimulation for Voiding Dysfunction (CP.MP.133) (PDF)
- Preventive Health and Clinical Practice Guidelines (CP.CPC.03) (PDF)
- PROM Testing (CP.MP.149) (PDF)
- Pulmonary Function Testing (CP.MP.242) (PDF)
- Radial Head Implant (CP.MP.148) (PDF)
- Radiofrequency Ablation of Uterine Fibroids (CP.MP.187) (PDF)
- Reduction Mammoplasty and Gynecomastia Surgery (CP.MP.51) (PDF)
- Sacroiliac Joint Infusion (CP.MP.126) (PDF)
- Sacroiliac Joint Interventions for Pain Management (CP.MP.166) (PDF)
- Sclerotherapy for Vericose Veins (CP.MP.146) (PDF)
- Selective Nerve Root Blocks and Transforaminal Epidural Injections (CP.MP.165) (PDF)
- Short Inpatient Hospital Stay (CP.MP. 182) (PDF)
- Skilled Nursing Facility Leveling (CP.MP.206) (PDF)
- Skin Substitutes for Chronic Wounds (CP.MP.185) (PDF)
- Sleep Center Polysomnography for Obstructive Sleep Apnea (CP.MP.248) (PDF)
- Spinal Cord, Peripheral, Nerve and Percutaneous (CP.MP.117) (PDF)
- Stereotatic Body Radiation Therapy (CP.MP.22) (PDF)
- Substance Use Treatment and Services (CP.BH.100) (PDF)
- Tandem Transplant (CP.MP.162) (PDF)
- Testing for Drugs of Abuse (CP.MP.50) (PDF)
- Testing for Select Genitourinary Conditions (CP.MP.97) (PDF)
- Thyroid Hormones and Insulin Testing in Pediatrics(CP.MP.154) (PDF)
- TMS for Treatment Resistant Major Depression (CP.BH.200) (PDF)
- Total Artificial Heart (CP.MP.127) (PDF)
- Total Parenteral Nutrition and Intradialytic Parenteral (CP.MP.163) (PDF)
- Transcranial Magnetic Stimulation (CP.BH.200) (PDF)
- Trigger Point Injections for Pain Management (CP.MP.169) (PDF)
- Ultrasound in Pregnancy (CP.MP.38) (PDF)
- Urinary Incontinence Devices and Treatments (CP.MP.142) (PDF)
- Urodynamic Testing (CP.MP.98) (PDF)
- Vagus Nerve Stimulation (CP.MP.12) (PDF)
- Ventricular Assist Devices (CP.MP.46) (PDF)
- Vitamin D Testing in Children (CP.MP.157) (PDF)
- Wheelchair Seating (CP.MP.99) (PDF)
- Wireless Motility Capsule (CP.MP.143) (PDF)
- Zika Virus Testing (CP.MP.111) (PDF)
Ambetter Pharmacy Policies
- Abaloparatide (Tymlos®) (CP.PHAR.345) (PDF)
- Abemaciclib (Verzenio™) (CP.PHAR.355) (PDF)
- Abiraterone (Zytiga) (CP.PHAR.84) (PDF)
- AbobotulinumtoxinA (Dysport®) (CP.PHAR.230) (PDF)
- Acalabrutinib (Calquence®) (CP.PHAR.366) (PDF)
- Acyclovir buccal tab (Sitavig) ophthalimic ointment (Avaclyr) (CP.PMN.210) (PDF)
- Ado-Trastuzumab Emtansine (Kadcyla®) (CP.PHAR.229) (PDF)
- Afamelanotide (Scenesse) (CP.PHAR.444) (PDF)
- Afatinib (Gilotrif®) (CP.PHAR.298) (PDF)
- Aflibercept (Eylea®) (CP.PHAR.184) (PDF)
- Agalsidase beta (Fabrazyme®) (CP.PHAR.158) (PDF)
- Age Limit Override (Codeine, Tramadol, Hydrocodone) (CP.PMN.138) (PDF)
- Alectinib (Alecensa®) (CP.PHAR.369) (PDF)
- Alemtuzumab (Lemtrada) (CP.PHAR.243) (PDF)
- Alendronate (Binosto®, Fosamax plus D®) (CP.PMN.88) (PDF)
- Alglucosidase alfa (Lumizyme®) (CP.PHAR.160) (PDF)
- Alirocumab (Praluent) (CP.PHAR.124) (PDF)
- Alosetron (Lotronex) (CP.PMN.153) (PDF)
- Alpelisib (Piqray) (CP.PHAR.430) (PDF)
- Alpha-1 Proteinase Inhibitors (CP.PHAR.94) (PDF)
- Amantadine ER (Gocovri®) (CP.PMN.89) (PDF)
- Ambrisentan (Letairis®) (CP.PHAR.190) (PDF)
- Amifampridine (Firdapse) (CP.PHAR.411) (PDF)
- Amikacin (Arikayce) (CP.PHAR.401) (PDF)
- Anti-inhibitor Coagulant Complex (Feiba®) (CP.PHAR.217) (PDF)
- Antipsychotic Therapy and Metabolic Monitoring (IN.CP.PMN.502) (PDF)
- Apalutamide (Erleada™) (CP.PHAR.376) (PDF)
- Aprepitant (Emend) (CP.PMN.19) (PDF)
- Arformoterol tartrate (Brovana) (CP.PMN.201) (PDF)
- Asenapine (Saphris®) (CP.PMN.15) (PDF)
- Asfotase Alfa (Strensiq®) (CP.PHAR.328) (PDF)
- Aspirin-dipyridamole (Aggrenox®) (CP.PMN.20) (PDF)
- Atezolizumab (Tecentriq®) (CP.PHAR.235) (PDF)
- Avatrombopag (Doptelet) (CP.PHAR.130) (PDF)
- Avelumab (Bavencio®) (CP.PHAR.333) (PDF)
- Axitinib (Inlyta®) (CP.PHAR.100) (PDF)
- Azacitidine (Vidaza) (CP.PHAR.387) (PDF)
- Aztreonam (Cayston®) (CP.PHAR.209) (PDF)
- Bedaquiline (Sirturo) (CP.PMN.212) (PDF)
- Belatacept (Nulojix®) (CP.PHAR.201) (PDF)
- Belimumab (Benlysta) (CP.PHAR.88) (PDF)
- Belinostat (Beleodaq®) (CP.PHAR.311) (PDF)
- Bendamustine (Bendeka®, Treanda®) (CP.PHAR.307) (PDF)
- Benralizumab (FasenraTM) (CP.PHAR.373) (PDF)
- Benzinadazole (CP.PMN.90) (PDF)
- Benzyl alcohol (Ulesfia) (CP.PMN.202) (PDF)
- Betaine (Cystadane) (CP.PHAR.143) (PDF)
- Betamethasone dipropionate (Sernivo) (CP.PMN.182) (PDF)
- Bevacizumab (Avastin®) (CP.PHAR.93) (PDF)
- Bexarotene (Targretin®) (CP.PHAR.75) (PDF)
- Bezlotoxumab (Zinplava®) (CP.PHAR.300) (PDF)
- Binimetinib (Mektovi®) (CP.PHAR.50) (PDF)
- Blinatumomab (Blincyto) (CP.PHAR.312) (PDF)
- Bortezomib (Velcade) (CP.PHAR.410) (PDF)
- Bosentan (Tracleer®) (CP.PHAR.191) (PDF)
- Bosutinib (Bosulif®) (CP.PHAR.105) (PDF)
- Brand Name Override (CP.PMN.22) (PDF)
- Brentuximab Vedotin (Adcetris) (CP.PHAR.303) (PDF)
- Brexanolone (Zulresso) (IN.CP.PHAR.417) (PDF)
- Brexpiprazole (Rexulti®) (CP.PMN.68) (PDF)
- Brigatinib (AlunbrigTM) (CP.PHAR.342) (PDF)
- Brimonidine (Mirvaso®) (CP.PMN.192) (PDF)
- Brodalumab (Siliq™) (CP.PHAR.375) (PDF)
- Brolucizumab (Beovu) (CP.PHAR.445) (PDF)
- Buprenorphine (Probuphine®, Sublocade®) (CP.PHAR.289) (PDF)
- Buprenorphine (Subutex®) (CP.PMN.82) (PDF)
- Buprenorphine and Buprenorphine/Naloxone Approval Criteria for MAT (CP.PMN.81) (PDF)
- Burosumab-twza (Crysvita) (CP.PHAR.11) (PDF)
- C1 Esterase Inhibitors (Berinert, Cinryze, Haegarda, Ruconest) (CP.PHAR.202) (PDF)
- Cabazitaxel (Jevtana®) (CP.PHAR.316) (PDF)
- Cabozantinib (Cabometyx, Cometriq) (CP.PHAR.111) (PDF)
- Calcifediol (Rayaldee®) (CP.PMN.76) (PDF)
- Canakinumab (Ilaris®) (CP.PHAR.246) (PDF)
- Capecitabine (Xeloda®) (CP.PHAR.60) (PDF)
- Caplacizumab-yhdp (Cablivi) (CP.PHAR.416) (PDF)
- Carfilzomib (Kyprolis®) (CP.PHAR.309) (PDF)
- Carglumic acid (Carbaglu®) (CP.PHAR.206) (PDF)
- Cariprazine (Vraylar®) (CP.PMN.91) (PDF)
- Celecoxib (Celebrex®) (CP.PMN.122) (PDF)
- Cenegermin-bkbj (Oxervate) (CP.PMN.186) (PDF)
- Ceritinib (Zykadia®) (CP.PHAR.349) (PDF)
- Cerliponase alfa (Brineura) (CP.PHAR.338) (PDF)
- Certolizumab (Cimzia) (CP.PHAR.247) (PDF)
- Cetuximab (Erbitux®) (CP.PHAR.317) (PDF)
- Chloramphenicol (CP.PHAR.388) (PDF)
- Ciclopirox (Penlac®) (CP.PMN.24) (PDF)
- Cholic acid (Cholbam) (CP.PHAR.390) (PDF)
- Cinacalcet (Sensipar) (CP.PHAR.61) (PDF)
- Cladribine (Mavenclad) (CP.PHAR.422) (PDF)
- Clobazam (Onfi) (CP.PMN.54) (PDF)
- Clozapine orally disintegrating tablet (Fazaclo®) (CP.PMN.12) (PDF)
- CNS Stimulants (CP.PMN.92) (PDF)
- Cobimetinib (Cotellic) (CP.PHAR.380) (PDF)
- Colchicine (Colcrys®) (CP.PMN.123) (PDF)
- Collagenase Clostridium Histolyticum (Xiaflex®) (CP.PHAR.82) (PDF)
- Copanlisib (Aliqopa®) (CP.PHAR.357) (PDF)
- Corticosteroid Intravitreal Implants (Iluvien, Ozurdex, Retisert) (CP.PHAR.385) (PDF)
- Corticotropin (H.P. Acthar) (CP.PHAR.168) (PDF)
- Cosyntropin (Cortrosyn®) (CP.PHAR.203) (PDF)
- Coverage of Diabetic Testing Meters and Strips (IN.PHAR.11) (PDF)
- Crisaborole (Eucrisa) (CP.PMN.110) (PDF)
- Crizotinib (Xalkori®) (CP.PHAR.90) (PDF)
- Cyclosporine (Restasis®) (CP.PMN.48) (PDF)
- Cysteamine ophthalmic (Cystaran™) (CP.PMN.130) (PDF)
- Cysteamine oral bitartrate (Cystagon®, Procysbi®) (CP.PHAR.155) (PDF)
- Cytomegalovirus Immune Globulin (CytoGam) (CP.PHAR.277) (PDF)
- Dabigatran (Pradaxa®) (CP.PMN.49) (PDF)
- Dabrafenib (Tafinlar) (CP.PHAR.239) (PDF)
- Dalfampridine (Ampyra) (CP.PHAR.248) (PDF)
- Dalteparin (Fragmin®) (CP.PHAR.225) (PDF)
- Daptomycin (Cubicin Cubicin RF) (CP.PHAR.351) (PDF)
- Daratumumab (Darzalex) (CP.PHAR.310) (PDF)
- Darbepoetin alfa (Aranesp®) (CP.PHAR.236) (PDF)
- Darolutamide (Nubeqa) (CP.PHAR.435) (PDF)
- Dasatinib (Sprycel®) (CP.PHAR.72) (PDF)
- Daunorubicin/Cytarabine (Vyxeos®) (CP.PHAR.352) (PDF)
- Deferasirox (Exjade, Jadenu) (CP.PHAR.145) (PDF)
- Deferiprone (Ferriprox) (CP.PHAR.147) (PDF)
- Deferoxamine (Desferal) (CP.PHAR.146) (PDF)
- Deflazacort (Emflaza®) (CP.PHAR.331) (PDF)
- Degarelix Acetate (Firmagon®) (CP.PHAR.170) (PDF)
- Delafloxacin (Baxdela®) (CP.PMN.115) (PDF)
- Denosumab (Prolia, Xgeva) (CP.PHAR.58) (PDF)
- Desmopressin (DDAVP®, Stimate®) (CP.PHAR.214) (PDF)
- Deutetrabenazine (Austedo®) (CP.PHAR.341) (PDF)
- Dextromethorphan-Quinidine (Nuedexta®) (CP.PMN.93) (PDF)
- Dimethyl fumarate (Tecfidera®) (CP.PHAR.249) (PDF)
- Dolasetron (Anzemet) (CP.PMN.141) (PDF)
- Dornase alfa (Pulmozyme®) (CP.PHAR.212) (PDF)
- Dose Optimization (CP.PMN.13) (PDF)
- Doxycycline Hyclate (Acticlate, Doryx), Doxycycline (Oracea) (CP.PMN.79) (PDF)
- DPP-4 inhibitors (CP.PMN.03) (PDF)
- Dronabinol (Marinol, Syndros) (CP.PMN.159) (PDF)
- Droxidopa (Northera®) (CP.PMN.17) (PDF)
- Dupilumab (Dupixent®) (IN.CP.PHAR.336) (PDF)
- Durvalumab (Imfinzi®) (CP.PHAR.339) (PDF)
- Dutasteride (Avodart®) and dutasteride/tamsulosin (Jalyn®) (CP.PMN.128) (PDF)
- Ecallantide (Kalbitor®) (CP.PHAR.177) (PDF)
- Eculizumab (Soliris®) (CP.PHAR.97) (PDF)
- Edaravone (Radicava™) (CP.PHAR.343) (PDF)
- Efinaconazole (Jublia®) (CP.PMN.25) (PDF)
- Elagolix (Orilissa) (CP.PHAR.136) (PDF)
- Eliglustat (Cerdelga®) (CP.PHAR.153) (PDF)
- Elosulfase alfa (Vimizim®) (CP.PHAR.162) (PDF)
- Elotuzumab (Empliciti®) (CP.PHAR.308) (PDF)
- Eltrombopag (Promacta®) (CP.PHAR.180) (PDF)
- Emapalumab-lzsg (Gamifant) (CP.PHAR.402) (PDF)
- Emicizumab-rzyl (Hemlibra) (CP.PHAR.370) (PDF)
- Enasidenib (Idhifa®) (CP.PHAR.363) (PDF)
- Encorafenib (Braftovi™) (CP.PHAR.127) (PDF)
- Enfuvirtide (Fuzeon) (CP.PHAR.41) (PDF)
- Enoxaparin (Lovenox) (CP.PHAR.224) (PDF)
- Enzalutamide (Xtandi) (CP.PHAR.106) (PDF)
- Epinephrine (EpiPen and EpiPen Jr) Quanity Limit Override (CP.PMN.144) (PDF)
- Epoetin Alfa (Epogen and Procrit) (CP.PHAR.237) (PDF)
- Epoprostenol (Flolan®, Veletri®) (CP.PHAR.192) (PDF)
- Erdafitinib (Balversa) (CP.PHAR.423) (PDF)
- Erenumab-aaoe (Aimovig) (CP.PHAR.128) (PDF)
- Eribulin Mesylate (Halaven®) (CP.PHAR.318) (PDF)
- Erlotinib (Tarceva®) (CP.PHAR.74) (PDF)
- Erwinia Asparaginase (Erwinaze®) (CP.PHAR.301) (PDF)
- Etanercept (Enbrel) (CP.PHAR.250) (PDF)
- Etelcalcetide (Parsabiv) (CP.PHAR.379) (PDF)
- Eteplirsen (Exondys 51®) (CP.PHAR.288) (PDF)
- Etidronate (Didronel®) (CP.PMN.94) (PDF)
- Everolimus (Afinitor, Afinitor Disperz) (CP.PHAR.63) (PDF)
- Evolocumab (Repatha) (CP.PHAR.123) (PDF)
- Febuxostat (Uloric®) (CP.PMN.57) (PDF)
- Fentanyl IR (Abstral, Actiq, Fentora, Lazanda, Subsys) (CP.PMN.127) (PDF)
- Ferric Carboxymaltose (Injectafer®) (CP.PHAR.234.) (PDF)
- Ferric Gluconate (Ferrlecit®) (CP.PHAR.166) (PDF)
- Ferric maltol (Accrufer) (CP.PMN.213) (PDF)
- Ferumoxytol (Feraheme®) (CP.PHAR.165) (PDF)
- Filgrastim (Neupogen), Filgrastim-sndz (Zarxio), Tbo-filgrastim (Granix) (CP.PHAR.297) (PDF)
- Fingolimod (Gilenya®) (CP.PHAR.251) (PDF)
- Fluticasone Propionate (Xhance®) (CP.PMN.95) (PDF)
- Fluticasone/Salmeterol (Advair Diskus, Advair HFA) (CP.PMN.31) (PDF)
- Fluticasone-umeclidinium-vilanterol (Trelegy Ellipta) (CP.PMN.146) (PDF)
- Fondaparinux (Arixtra®) (CP.PHAR.226) (PDF)
- Fostamatinib (Tavalisse) (CP.PHAR.24) (PDF)
- Fremanezumab (Ajovy) (CP.PHAR.403) (PDF)
- Fulvestrant (Faslodex Injection) (CP.PHAR.424) (PDF)
- Galcanezumab-gnlm (Emgality) (CP.PHAR.404) (PDF)
- Galsulfase (Naglazyme®) (CP.PHAR.161) (PDF)
- Gefitinib (Iressa®) (CP.PHAR.68) (PDF)
- Glasdegib (Daurismo) (CP.PHAR.413) (PDF)
- Gemtuzumab ozogamicin (Mylotarg®) (CP.PHAR.358) (PDF)
- Gilteritinib (Xospata) (CP.PHAR.412) (PDF)
- GLP-1 receptor agonists (CP.PMN.183) (PDF)
- Glycerol phenylbutyrate (Ravicti®) (CP.PHAR.207) (PDF)
- Golimumab (Simponi®, Simponi Aria®) (CP.PHAR.253) (PDF)
- Goserelin Acetate (Zoladex®) (CP.PHAR.171) (PDF)
- Granisetron (Kytril, Sancuso) (CP.PMN.74) (PDF)
- Guselkumab (Tremfya®) (CP.PHAR.364) (PDF)
- Halobetasol-Tazarotene (Duobrii) (CP.PMN.208) (PDF)
- Hemin (Panhematin®) (CP.PHAR.181) (PDF)
- Histrelin Acetate (Vantas®, Supprelin LA®) (CP.PHAR.172) (PDF)
- House dust mite allergen extract (Odactra®) (CP.PMN.111) (PDF)
- Hyaluronate Derivatives (CP.PHAR.05) (PDF)
- Hydroxyurea (Siklos) (CP.PMN.193) (PDF)
- Ibalizumab-uiyk (Trogarzo™) (CP.PHAR.378) (PDF)
- Ibandronate injection (Boniva®) (CP.PHAR.189) (PDF)
- Ibandronate Oral (Boniva®) (CP.PMN.96) (PDF)
- Ibrutinib (Imbruvica) (CP.PHAR.126) (PDF)
- Ibuprofen and Famotidine (Duexis) (CP.PMN.120) (PDF)
- Icatibant (Firazyr®) (CP.PHAR.178) (PDF)
- Icosapent ethyl (Vascepa) (CP.PMN.187) (PDF)
- Idelalisib (Zydelig) (CP.PHAR.133) (PDF)
- Idursulfase (Elaprase®) (CP.PHAR.156) (PDF)
- Ifaximin (Xifaxan®) (CP.PMN.47) (PDF)
- Iloperidone (Fanapt®) (CP.PMN.32) (PDF)
- Iloprost (Ventavis®) (CP.PHAR.193) (PDF)
- Imatinib mesylate (Gleevec®) (CP.PHAR.65) (PDF)
- Imiglucerase (Cerezyme®) (CP.PHAR.154) (PDF)
- Immune Globulins (CP.PHAR.103) (PDF)
- Immunization Coverage (CP.PHAR.28) (PDF)
- IncobotulinumtoxinA (Xeomin®) (CP.PHAR.231) (PDF)
- Indacaterol (Arcapta Neohaler) (CP.PMN.203) (PDF)
- Indacaterol-glycopyrrolate (Utibron Neohaler) (CP.PMN.147) (PDF)
- Infliximab (Remicade®, Inflectra®, Renflexis™) (CP.PHAR.254) (PDF)
- Inotersen (Tegsedi) (CP.PHAR.405) (PDF)
- Inotuzumab ozogamicin (Besponsa®) (CP.PHAR.359) (PDF)
- Interferon beta-1a (Avonex®, Rebif®) (CP.PHAR.255) (PDF)
- Interferon beta-1b (Betaseron®, Extavia®) (CP.PHAR.256) (PDF)
- Interferon Gamma- 1b (Actimmune®) (CP.PHAR.52) (PDF)
- Intra baclofen (Gablofen®) (CP.PHAR.149) (PDF)
- Ipilimumab (Yervoy) (CP.PHAR.319) (PDF)
- Irinotecan Liposome (Onivyde®) (CP.PHAR.304) (PDF)
- Iron Sucrose (Venofer®) (CP.PHAR.167) (PDF)
- Isavuconazonium (Cresemba) (CP.PMN.154) (PDF)
- Isotretinoin (Claravis, Absorica, Myorisan, Zenatane) (CP.PMN.143) (PDF)
- Istradefylline (Nourianz) (CP.PMN.217) (PDF)
- Itraconazole (Sporanox®, Onmel®) (CP.PMN.124) (PDF)
- Ivabradine (Corlanor®) (CP.PMN.70) (PDF)
- Ivosidenib (Tibsovo) (CP.PHAR.137) (PDF)
- Ixazomib (Ninlaro) (CP.PHAR.302) (PDF)
- Ixekizumab (Taltz®) (CP.PHAR.257) (PDF)
- Lacosamide (Vimpat) (CP.PMN.155) (PDF)
- Lanadelumab-fylo (Takhzyro) (CP.PHAR.396) (PDF)
- Lanreotide (Somatuline Depot) (CP.PHAR.391) (PDF)
- Lantanoprostene Bunod (Vyzylta®) (CP.PMN.108) (PDF)
- Lapatinib (Tykerb®) (CP.PHAR.79) (PDF)
- Laronidase (Aldurazyme®) (CP.PHAR.152) (PDF)
- Larotrectinib (Vitrakvi) (CP.PHAR.414) (PDF)
- Lasmiditan (Reyvow) (CP.PMN.218) (PDF)
- Lefamulin (Xenleta) (CP.PMN.219) (PDF)
- Lenalidomide (Revlimid®) (CP.PHAR.71) (PDF)
- Lenvatinib (Lenvima) (CP.PHAR.138) (PDF)
- Lesinurad (Zurampic), lesinurad-allopurinol (Duzallo) (CP.PMN.150) (PDF)
- Letermovir (Prevymis®) (CP.PHAR.367) (PDF)
- Leucovorin Injection (CP.PHAR.393) (PDF)
- Leuprolide Acetate (Eligard®, Lupaneta Pack®, Lupron Depot®, Lupron Depot-Ped®) (CP.PHAR.173) (PDF)
- Levoleucovorin (Fusilev®) (CP.PHAR.151) (PDF)
- L-glutamine (Endari®) (CP.PMN.116) (PDF)
- Lidocaine Transdermal (Lidoderm®) (CP.PMN.08) (PDF)
- Lifitegrast (Xiidra®) (CP.PMN.73) (PDF)
- Linaclotide (Linzess®) (CP.PMN.71) (PDF)
- Lindane Shampoo (CP.PMN.09) (PDF)
- Linezolid (Zyvox®) (CP.PMN.27) (PDF)
- Lomitapide (Juxtapid) (CP.PHAR.283) (PDF)
- Lorcaserin (Belviq®, Belviq XR®) (CP.PCH.03) (PDF)
- Lorlatinib (Lorbrena) (CP.PHAR.406) (PDF)
- Lubiprostone (Amitiza) (CP.PMN.142) (PDF)
- Luliconazole Cream (Luzu) (CP.PMN.166) (PDF)
- Lurasidone (Latuda®) (CP.PMN.50) (PDF)
- Lusutrombopag (Mulpleta) (CP.PHAR.407) (PDF)
- Lutetium Lu 177 dotatate (Lutathera) (CP.PHAR.384) (PDF)
- Macitentan (Opsumit®) (CP.PHAR.194) (PDF)
- Mecamylamine (Vecamyl®) (CP.PMN.136) (PDF)
- Mecasermin (Increlex) (CP.PHAR.150) (PDF)
- Mechlorethamine (Valchlor) (CP.PHAR.381) (PDF)
- Mepolizumab (Nucala) (CP.PHAR.200) (PDF)
- Mercaptopurine (Purixan) (CP.PHAR.447) (PDF)
- Metformin ER (Glumetza®) (CP.PMN.72) (PDF)
- Methadone for Management of Pain (IN.CP.PMN.02) (PDF)
- Methotrexate (Otrexup, Rasuvo, Xatmep) (CP.PHAR.134) (PDF)
- Methoxy polyethylene glycol-epoetin beta (Mircera®) (CP.PHAR.238) (PDF)
- Metreleptin (Myalept) (CP.PHAR.425) (PDF)
- Midostaurin (Rydapt) (CP.PHAR.344) (PDF)
- Mifepristone (Korlym®) (CP.PHAR.101) (PDF)
- Migalastat (Galafold) (CP.PHAR.394) (PDF)
- Miglustat (Zavesca®) (CP.PHAR.164) (PDF)
- Minocycline ER (Solodyn®) and Microspheres (Arestin®) (CP.PMN.80) (PDF)
- Mipomersen (Kynamro) (CP.PHAR.284) (PDF)
- Mitoxantrone (Novantrone®) (CP.PHAR.258) (PDF)
- Mogamulizumab-kpkc (Poteligeo) (CP.PHAR.139) (PDF)
- Mometasone furoate (Sinuva) (CP.PHAR.448) (PDF)
- Nabilone (Cesamet) (CP.PMN.160) (PDF)
- Nafarelin Acetate (Synarel®) (CP.PHAR.174) (PDF)
- Naldemedine (Symproic®) (CP.PMN.112) (PDF)
- Naloxone (Evzio) (CP.PMN.139) (PDF)
- Naltrexone (Vivitrol®) (CP.PHAR.96) (PDF)
- Naproxen and esomeprazole magnesium (Vimovo®) (CP.PMN.117) (PDF)
- Narcolepsy Agents (IN.CP.PMN.500) (PDF)
- Natalizumab (Tysabri®) (CP.PHAR.259) (PDF)
- Necitumumab (Portrazza®) (CP.PHAR.320) (PDF)
- Neratinib (Nerlynx®) (CP.PHAR.365) (PDF)
- Netarsudil (Rhopressa®) (CP.PMN.118) (PDF)
- Netupitant;palonosetron (Akynzeo) (CP.PMN.158) (PDF)
- Nilotinib (Tasigna®) (CP.PHAR.76) (PDF)
- Nintedanib (Ofev) (CP.PHAR.285) (PDF)
- Niraparib (Zejula) (CP.PHAR.408) (PDF)
- Nitisinone (Orfadin, Nityr) (CP.PHAR.132) (PDF)
- Nivolumab (Opdivo) (CP.PHAR.121) (PDF)
- No Coverage Criteria/Off-Label Use Policy (CP.PMN.53) (PDF)
- Non-Calcium Phosphate Binders (CP.PMN.04) (PDF)
- Nusinersen (Spinraza) (CP.PHAR.327) (PDF)
- Obeticholic acid (Ocaliva) (CP.PHAR.287) (PDF)
- Obinutuzumab (Gazyva®) (CP.PHAR.305) (PDF)
- Ocrelizumab (OcrevusTM) (CP.PHAR.335) (PDF)
- Octreotide Acetate (Sandostatin®, Sandostatin LAR Depot®) (CP.PHAR.40) (PDF)
- Ofatumumab (Arzerra®) (CP.PHAR.306) (PDF)
- Olanzapine ODT (Zyprexa Zydis®) (CP.PMN.29) (PDF)
- Olaparib (Lynparza) (CP.PHAR.360) (PDF)
- Olaratumab (Lartruvo®) (CP.PHAR.326) (PDF)
- Olodaterol (Striverdi Respimat) (CP.PMN.204) (PDF)
- Omacetaxine (Synribo®) (CP.PHAR.108) (PDF)
- Omadacycline (Nuzyra) (CP.PMN.188) (PDF)
- Omalizumab (Xolair®) (CP.PHAR.01) (PDF)
- Omega-3-Acid Ethyl Esters (Lovaza®) (CP.PMN.52) (PDF)
- OnabotulinumtoxinA (Botox) (CP.PHAR.232) (PDF)
- Ondansetron (Zuplenz) (CP.PMN.45) (PDF)
- Opiates with concurrent buprenorphine (Subutex®) and buprenorphine naloxone (Suboxone®) (CP.PMN.47) (PDF)
- Opioid Analgesics (CP.PMN.97) (PDF)
- Opioid Analgesics (IN.CP.PPA.12) (PDF)
- Osimertinib (Tagrisso) (CP.PHAR.294) (PDF)
- Overactive Bladder Agents (CP.PMN.198) (PDF)
- Oxymetazoline (Rhofade™) (CP.PMN.86) (PDF)
- Ozenoxacin (Xepi) (CP.PMN.119) (PDF)
- Paclitaxel, protein-bound (Abraxane®) (CP.PHAR.176) (PDF)
- Palbociclib (Ibrance®) (CP.PHAR.125) (PDF)
- Palivizumab (Synagis®) (CP.PHAR.16) (PDF)
- Panitumumab (Vectibix®) (CP.PHAR.321) (PDF)
- Panobinostat (Farydak) (CP.PHAR.382) (PDF)
- Parathyroid hormone (Natpara) (CP.PHAR.282) (PDF)
- Paricalcitol Injection (Zemplar) (CP.PHAR.270) (PDF)
- Pasireotide (Signifor LAR®) (CP.PHAR.332) (PDF)
- Patiromer (Veltassa) (CP.PMN.205) (PDF)
- Patisiran (Onpattro) (CP.PHAR.395) (PDF)
- Pazopanib (Votrient®) (CP.PHAR.81) (PDF)
- Peanut Allergen Powder (Palforzia) (CP.PMN.220) (PDF)
- Pegademase Bovine (Adagen) (CP.PHAR.392) (PDF)
- Pegaptanib (Macugen®) (CP.PHAR.185) (PDF)
- Pegaspargase (Oncaspar®) (CP.PHAR.353) (PDF)
- Pegfilgrastim (Neulasta) (CP.PHAR.296) (PDF)
- Peginterferon Alfa-2b (PegIntron, Sylatron) (CP.PHAR.89) (PDF)
- Peginterferon beta-1a (Plegridy®) (CP.PHAR.271) (PDF)
- Pegloticase (Krystexxa®) (CP.PHAR.115) (PDF)
- Pegvaliase-pqpz (Palynziq) (CP.PHAR.140) (PDF)
- Pegvisomant (Somavert) (CP.PHAR.389) (PDF)
- Pembrolizumab (Keytruda®) (CP.PHAR.322) (PDF)
- Pemetrexed (Alimta®) (CP.PHAR.368) (PDF)
- Perampanel (Fycompa) (CP.PMN.156) (PDF)
- Pertuzumab (Perjeta®) (CP.PHAR.227) (PDF)
- Pexidartinib (Turalio) (CP.PHAR.436) (PDF)
- Pimavanserin (Nuplazid) (CP.PMN.140) (PDF)
- Pirfenidone (Esbriet) (CP.PHAR.286) (PDF)
- Plecanatide (Trulance®) (CP.PMN.87) (PDF)
- Plerixafor (Mozobil) (CP.PHAR.323) (PDF)
- Polatuzuman vedotin – piiq (Polivy) (CP.PHAR.433) (PDF)
- Pomalidomide (Pomalyst®) (CP.PHAR.116) (PDF)
- Ponatinib (Iclusig®) (CP.PHAR.112) (PDF)
- Pralatrexate (Folotyn®) (CP.PHAR.313) (PDF)
- Pramlintide (Symlin®) (CP.PMN.129) (PDF)
- Prasterone (Intrarosa®) (CP.PMN.99) (PDF)
- Pregabalin (Lyrica, Lyrica CR) (CP.PMN.33) (PDF)
- Pretomanid (CP.PMN.222) (PDF)
- Propranolol HCl oral solution (Hemangeol®) (CP.PMN.58) (PDF)
- Protein C Concentrate Human (Ceprotin®) (CP.PHAR.330) (PDF)
- Prucalopride (Motegrity) (CP.PMN.194) (PDF)
- Pyrimethamine (Daraprin®) (CP.PMN.44) (PDF)
- QL of Diabetic Test Strips not receiving insulin (CP.PMN.151) (PDF)
- Quantity Limit Override (CP.PMN.59) (PDF)
- Quetiapine ER (Seroquel XR®) (CP.PMN.64) (PDF)
- Ramucirumab (Cyramza®) (CP.PHAR.119) (PDF)
- Ranibizumab (Lucentis®) (CP.PHAR.186) (PDF)
- Ranolazine (Ranexa®) (CP.PMN.34) (PDF)
- Ravulizumab-cwvz (Ultomiris) (CP.PHAR.415) (PDF)
- Regorafenib (Stivarga®) (CP.PHAR.107) (PDF)
- Request for Medically Necessary Drug not on the PDL (CP.PMN.16) (PDF)
- Reslizumab (Cinqair®) (CP.PHAR.223) (PDF)
- Revefenacin (Yupelri) (CP.PMN.195) (PDF)
- Ribavirin (Copegus, Moderiba, Rebetol, Ribasphere) (CP.PHAR.141) (PDF)
- Ribociclib (Kisqali®, Kisqali Femara®) (CP.PHAR.334) (PDF)
- Rifabutin (Mycobutin),Rifabutin,omeprazole,amoxicillin (Talicia) (CP.PMN.223) (PDF)
- Rifamycin (Aemcolo) (CP.PMN.196) (PDF)
- Rifapentine (Priftin®) (CP.PMN.05) (PDF)
- Rilonacept (Arcalyst®) (CP.PHAR.266) (PDF)
- RimabotulinumtoxinB (Myobloc®) (CP.PHAR.233) (PDF)
- Riociguat (Adempas®) (CP.PHAR.195) (PDF)
- Risankizumab-rsaa (Skyrizi) (CP.PHAR.426) (PDF)
- Risedronate (Actonel®, Atelvia®) (CP.PMN.100) (PDF)
- Rituximab (Rituxan®), Rituximab and hyaluronidase (Rituxan Hycela™) (CP.PHAR.260) (PDF)
- Rivastigmine (Exelon®) (CP.PMN.101) (PDF)
- Roflumilast (Daliresp) (CP.PMN.46) (PDF)
- Rolapitant (Varubi®) (CP.PMN.102) (PDF)
- Romidepsin (Istodax®) (CP.PHAR.314) (PDF)
- Romiplostim (Nplate®) (CP.PHAR.179) (PDF)
- Romosozumab-aqqg (Evenity) (CP.PHAR.428) (PDF)
- Rucaparib (Rubraca®) (CP.PHAR.350) (PDF)
- Rufinamide (Banzel) (CP.PMN.157) (PDF)
- Ruxolitinib (Jakafi®) (CP.PHAR.98) (PDF)
- Sacubitril and Valsartan (Entresto®) (CP.PMN.67) (PDF)
- Safinamide (Xadago®) (CP.PMN.113) (PDF)
- Sapropterin (Kuvan®) (CP.PHAR.43) (PDF)
- Sarecycline (Seysara) (CP.PMN.189) (PDF)
- Sargramostim (Leukine) (CP.PHAR.295) (PDF)
- Sarilumab (Kevzara®) (CP.PHAR.346) (PDF)
- Sebelipase alfa (Kanuma®) (CP.PHAR.159) (PDF)
- Secnidazole (Solosec®) (CP.PMN.103) (PDF)
- Secukinumab (Cosentyx®) (CP.PHAR.261) (PDF)
- Segesterone-Ethinyl Estradiol (Annovera) (CP.PMN.190) (PDF)
- Selexipag (Uptravi®) (CP.PHAR.196) (PDF)
- Selinexor (Xpovio) (CP.PHAR.431) (PDF)
- Short Ragweed Pollen Allergen Extract (Ragwitek) (CP.PMN.83) (PDF)
- Sildenafil (Revatio®) (CP.PHAR.197) (PDF)
- Siltuximab (Sylvant®) (CP.PHAR.329) (PDF)
- Siponimod (Mayzent) (CP.PHAR.427) (PDF)
- Sipuleucel-T (Provenge®) (CP.PHAR.120) (PDF)
- Sodium phenylbutyrate (Buphenyl®) (CP.PHAR.208) (PDF)
- Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors (CP.PMN.14) (PDF)
- Solriamfetol (Sunosi) (CP.PMN.209) (PDF)
- Sonidegib (Odomzo®) (CP.PHAR.272) (PDF)
- Sorafenib (Nexavar®) (CP.PHAR.69) (PDF)
- SSRI SNRI Duplicate Thearapy (CP.PMN.60) (PDF)
- Step Therapy (CP.PST.01) (PDF)
- Sunitinib (Sutent®) (CP.PHAR.73) (PDF)
- Suvorexant (Belsomra®) (CP.PMN.109) (PDF)
- Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens Allergen Extract (Oralair) (CP.PMN.85) (PDF)
- Tadalafil (Adcirca®) (CP.PHAR.198) (PDF)
- Tadalafil BHP - ED (Cialis) (CP.PMN.132) (PDF)
- Tafamidis meglumine, Tafamidis (Vyndaquel, Vyndamax) (CP.PHAR.432) (PDF)
- Tafenoquine (Arakoda) (CP.PMN.178) (PDF)
- Talazoparib (Talzenna) (CP.PHAR.409) (PDF)
- Taliglucerase alfa (Elelyso®) (CP.PHAR.157) (PDF)
- Tasimelteon (Hetlioz®) (CP.PMN.104) (PDF)
- Tavaborole (Kerydin®) (CP.PMN.105) (PDF)
- Tedizolid (Sivextro®) (CP.PMN.62) (PDF)
- Teduglutide (Gattex) (CP.PHAR.114) (PDF)
- Tegaserod (Zelnorm) (CP.PMN.206) (PDF)
- Telotristat ethyl (Xermelo™) (CP.PHAR.337) (PDF)
- Temozolomide (Temodar®) (CP.PHAR.77) (PDF)
- Temsirolimus (Torisel®) (CP.PHAR.324) (PDF)
- Tenapanor (Ibsrela) (CP.PMN.224) (PDF)
- Teriflunomide (Aubagio®) (CP.PHAR.262) (PDF)
- Teriparatide (Forteo®) (CP.PHAR.188) (PDF)
- Tesamorelin (Egrifta) (CP.PHAR.109) (PDF)
- Testosterone Pellet (Testopel®) (CP.PHAR.354) (PDF)
- Tetrabenazine (Xenazine®) (CP.PHAR.92) (PDF)
- Tezacaftor/iv acafter; ivacaftor (Symdeko™ ) (CP.PHAR.377) (PDF)
- Thalidomide (Thalomid) (CP.PHAR.78) (PDF)
- Thioguanine (Tabloid) (CP.PHAR.437) (PDF)
- Thyrotropin Alfa (Thyrogen) (CP.PHAR.95) (PDF)
- Tildrakizumab-asmn (Ilumya) (CP.PHAR.386) (PDF)
- Timothy Grass Pollen Allergen Extract (Grastek) (CP.PMN.84) (PDF)
- Tiotropium-olodaterol (Stiolto Respimat) (CP.PMN.148) (PDF)
- Tisagenlecleucel (Kymriah®) (CP.PHAR.361) (PDF)
- Tobramycin (CP.PHAR.211) (PDF)
- Tocilizumab (Actemra®) (CP.PHAR.263) (PDF)
- Tofacitinib (Xeljanz®, Xeljanz® XR) (CP.PHAR.267) (PDF)
- Tolvaptan (Jynarque) (CP.PHAR.27) (PDF)
- Topical Immunomodulators (CP.PMN.107) (PDF)
- Topotecan (Hycamtin®) (CP.PHAR.64) (PDF)
- Toremifene (Fareston®) (CP.PMN.126) (PDF)
- Trametinib (Mekinist) (CP.PHAR.240) (PDF)
- Trastuzumab (Herceptin®), Trastuzumab-dkst (Ogivri®) (CP.PHAR.228) (PDF)
- Treprostinil (Orenitram®, Remodulin®, Tyvaso®) (CP.PHAR.199) (PDF)
- Triclabendazole (Egaten) (CP.PMN.207) (PDF)
- Triamcinolone ER Injection (Zilretta) (CP.PHAR.371) (PDF)
- Trientine (Syprine) (CP.PHAR.438) (PDF)
- Trifarontene (Aklief) (CP.PMN.225) (PDF)
- Trifluridine_Tipiracil (Lonsurf) (CP.PHAR.383) (PDF)
- Triptorelin Pamoate (Trelstar®, Triptodur®) (CP.PHAR.175) (PDF)
- Umeclidinium-vilanterol (Anoro Ellipta) (CP.PMN.149) (PDF)
- Ustekinumab (Stelara®) (CP.PHAR.264) (PDF)
- Valbenazine (Ingrezza™) (CP.PHAR.340) (PDF)
- Valproate (Depacon) (CP.PHAR.429) (PDF)
- Valrubicin (Valstar) (CP.PHAR.439) (PDF)
- Vandetanib (Caprelsa®) (CP.PHAR.80) (PDF)
- Vedolizumab (Entyvio®) (CP.PHAR.265) (PDF)
- Velaglucerase alfa (VPRIV®) (CP.PHAR.163) (PDF)
- Vemurafenib (Zelboraf®) (CP.PHAR.91) (PDF)
- Verteporfin (Visudyne®) (CP.PHAR.187) (PDF)
- Vestronidase alfa-vjbk (Mepsevii™) (CP.PHAR.374) (PDF)
- Vigabatrin (Sabril) (CP.PHAR.169) (PDF)
- Vincristine Sulfate Liposome Injection (Marqibo®) (CP.PHAR.315) (PDF)
- Vismodegib (Erivedge®) (CP.PHAR.273) (PDF)
- Voretigene Neparvovec-rzyl (Luxturna) (CP.PHAR.372) (PDF)
- Vorinostat (Zolinza®) (CP.PHAR.83) (PDF)
- Ziv-aflibercept (Zaltrap®) (CP.PHAR.325) (PDF)
- Zoledronic Acid (Reclast®, Zometa®) (CP.PHAR.59) (PDF)
Payment Policies
Health care claims payment policies are guidelines used to assist in administering payment rules based on generally accepted principles of correct coding. They are used to help identify whether health care services are correctly coded for reimbursement. Each payment rule is sourced by a generally accepted coding principle. They include, but are not limited to claims processing guidelines referenced by the Centers for Medicare and Medicaid Services (CMS), Publication 100-04, Claims Processing Manual for physicians/non-physician practitioners, the CMS National Correct Coding Initiative policy manual (procedure-to-procedure coding combination edits and medically unlikely edits), Current Procedural Technology guidance published by the American Medical Association (AMA) for reporting medical procedures and services, health plan clinical policies based on the appropriateness of health care and medical necessity, and at times state-specific claims reimbursement guidance.
All policies found in the MHS Payment Policy Manual apply with respect to MHS members. Policies in the MHS Payment Policy Manual may have either a MHS or a “Centene” heading. In addition, MHS may from time to time employ a vendor that applies payment policies to specific services; in such circumstances, the vendor’s guidelines may also be used to determine whether a service has been correctly coded. Other policies (e.g., clinical policies) or contract terms may further determine whether a technology, procedure or treatment that is not addressed in the Payment Policy Manual is payable by MHS.
If you have any questions regarding these policies, please contact Member Services and ask to be directed to the Medical Management department.
Ambetter Payment Policies
- 30 Day Readmission (CC.PP.501) (PDF)
- Add on Code Billed Without Primary Code (CC.PP.030) (PDF)
- ADHD Assessment and Treatment (CP.MP.124) (PDF)
- Allergy Testing and Therapy (CP.MP.100) (PDF)
- Ambulatory EEG (CP.MP.96) (PDF)
- Assistant Surgeon (CC.PP.029) (PDF)
- Behavioral Health Treatment Document Requirement (CP.BH.500) (PDF)
- Bevacizumab (Avastin®) (CP.PHAR.93) (PDF)
- Bilateral Procedures (CC.PP.037) (PDF)
- Bronchial Thermoplasty (CP.MP.110) (PDF)
- Cardiac Biomarker Testing (CP.MP.156) (PDF)
- Cerumen Removal (CC.PP.008) (PDF)
- Clean Claims (CC.PP.021) (PDF)
- Code Editing Overview (CC.PP.011) (PDF)
- Cosmetic Procedures (CC.PP.024) (PDF)
- Digital Electroencephalography Spike Analysis (CP.MP.105) (PDF)
- Distinct Procedural Modifiers: XE, XS, XP, & XU (CC.PP.020) (PDF)
- Drugs of Abuse: Definitive Testing (CP.MP.50) (PDF)
- Duplicate Primary Code Billing (CC.PP.044) (PDF)
- E&M Bundling with Labs and Radiology (CC.PP.010) (PDF)
- E&M Medical Decision-Making (CC.PP.051) (PDF)
- E&M Services Billed with Treatment Room Revenue Codes (CC.PP.071) (PDF)
- EEG in the Evaluation of Headache (CP.MP.155) (PDF)
- Electroencephalography in the Evaluation of Headache (CP.MP.155) (PDF)
- Endometrial Ablation (CP.MP.106) (PDF)
- Evoked Potential Testing (CP.MP.134) (PDF)
- Fecal Calprotectin Assay (CP.MP.135) (PDF)
- GI Pathogen Nucleic Acid Detection Panel Testing (CP.MP.209) (PDF)
- Global Maternity Billing (CC.PP.016) (PDF)
- Holter Monitors (CP.MP.113) (PDF)
- Homocysteine Testing (CP.MP.121) (PDF)
- Hospital Visit Codes Billed with Labs (CC.PP.023) (PDF)
- Inpatient Consultation (CC.PP.038) (PDF)
- Inpatient Only Procedures (MP.PP.018) (PDF)
- Intravenous Hydration (CC.PP.012) (PDF)
- Laser Therapy for Skin Conditions (CP.MP.123) (PDF)
- Low-frequency Ultrasound and Noncontact Normothermic Wound Therapy (CP.MP.139) (PDF)
- Maximum Units (CC.PP.007) (PDF)
- Measurement of Serum 1,25-dihydroxyvitamin D (CP.MP.152) (PDF)
- Mechanical Stretching Devices for Joint Stiffness and Contracture (CP.MP.144) (PDF)
- Moderate Conscious Sedation (CC.PP.015) (PDF)
- Modifier DOS Validation (CC.PP.034) (PDF)
- Modifier to Procedure Code Validation (CC.PP.028) (PDF)
- Multiple CPT Code Replacement (CC.PP.033) (PDF)
- Multiple Diagnostic Cardiovascular Procedure Payment Reduction (CC.PP.065) (PDF)
- NCCI Unbundling (CC.PP.031) (PDF)
- Never Paid Events (CC.PP.017) (PDF)
- New Patient (CC.PP.036) (PDF)
- Not Medically Necessary Inpatient Services (CC.PP.060) (PDF)
- Outpatient Consultation (CC.PP.039) (PDF)
- Paclitaxel, Protein-bound (Abraxane) (CP.PHAR.176) (PDF)
- Physician's Consultation Services (CC.PP.054) (PDF)
- Physician's Office Lab Testing (CC.PP.055) (PDF)
- Place of Service Mismatch (CC.PP.063) (PDF)
- Polymerase Chain Reaction Respiratory Viral Panel Testing (CP.MP.181) (PDF)
- Post-Operative Visits (CC.PP.042) (PDF)
- Pre-Operative Visits (CC.PP.041) (PDF)
- Problem-Oriented Visits with Preventative Visits (CC.PP.057) (PDF)
- Professional Component (CC.PP.027) (PDF)
- Professional Services (Visit Codes) Billed With Labs (CC.PP.019) (PDF)
- Proton and Neutron Beam Therapy (CP.MP.70) (PDF)
- Pulmonary Function Testing (CP.MP.242) (PDF)
- Pulse Oximetry (CC.PP.025) (PDF)
- Robotic Surgery (CC.PP.050) (PDF)
- Sepsis Diagnosis (CP.PP.073) (PDF)
- Sleep Studies Place of Services (CC.PP.035) (PDF)
- Status "B" Bundled Services (CC.PP.046) (PDF)
- Status P Bundled Services (CC.PP.049) (PDF)
- Supplies Billed on Same Day As Surgery (CC.PP.032) (PDF)
- Testing for Select Genitourinary Conditions (CP.MP.97) (PDF)
- Transgender Related Services (CC.PP.047) (PDF)
- Ultrasound in Pregnancy (CP.MP.38) (PDF)
- Unbundled Professional Services (CC.PP.043) (PDF)
- Unbundled Surgical Procedures (CC.PP.045) (PDF)
- Unlisted Procedure Codes (CC.PP.009) (PDF)
- Urine Specimen Validity Testing (CC.PP.056) (PDF)
- Urodynamic Testing (CP.MP.98) (PDF)
- Visits On Same Day As Surgery (CC.PP.040) (PDF)
- Wheelchair Accessories (CC.PP.502) (PDF)
- Wheelchair Seating (CP.MP.99) (PDF)
- Wireless Motility Capsule (CP.MP.143) (PDF)